Welcome

By clicking "Continue to the HCP site," you are certifying that you are a licensed US healthcare professional (HCP) and a US resident.

If you are a patient who wants to learn more about VASCEPA, click vascepa.com

Helpful resources for pharmacists dispensing VASCEPA prescriptions

The Omega-3 Quiz

You may not know as much as you think about omega-3s. Take this short quiz to find out how omega-3s stack up against other treatments.

Take the quiz

Downloadable Resources

Indication Differences Between VASCEPA and Generic Omega-3s

Indication Differences Between VASCEPA and Generic Omega-3s

Information on indication differences for VASCEPA and Lovaza® (omega-3-acid ethyl esters) and its generics

Download

Common DAW Codes

Common DAW Codes

A quick and easy reference sheet for pharmacists to use to ensure that VASCEPA is dispensed properly

Download

VASCEPA Access & Coverage

VASCEPA Access & Coverage

Information on VASCEPA access and savings

Download

Pharmacy Education Guide

Pharmacy Education Guide

See how your patients can save more on VASCEPA compared to the generic

Download

Retail Fact Sheet

Retail Fact Sheet

See the retail information for VASCEPA

Download

VASCEPA Savings Card

VASCEPA Savings Card

Learn how eligible patients can sign up to save on VASCEPA with the universal VASCEPA Savings Card.*

For eligible patients only. Maximum savings and other terms and conditions apply. See https://vascepa.copaysavingsprogram.com for details.

Important Information About Dispensing VASCEPA

Important Information About Dispensing VASCEPA

  • When generic IPE is automatically substituted for VASCEPA, but the generic is not in stock, some patients won’t come back for their prescription—interrupting their therapy
  • Stock and dispense VASCEPA as written to minimize any disruption in patient care
  • Watch out for unintended substitutions and claim rejections. Look for “Dispense as written (DAW-1)” or “Brand medically necessary” to help ensure your patients are getting the CV benefits of VASCEPA1

Download

Virtual Speaker Programs

Join your peers at convenient times as they discuss how your statin-treated patients can benefit from VASCEPA

Register now

On-Demand Expert Perspectives

Expert Perspective: Dr. Canto

Dr. Canto headshot

Watch Dr. John Canto highlight the urgency to treat Persistent Cardiovascular Risk (P-CVR) and the role of VASCEPA

Register and watch

This site uses cookies to give you the best possible experience. By browsing our website, you agree to our use of cookies. If you require further information and/or do not wish to have cookies placed when using the site, visit the Privacy Policy page.

IMPORTANT SAFETY INFORMATION

• VASCEPA is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to VASCEPA or any of its components

• VASCEPA was associated with an increased risk (3% vs 2%) of atrial fibrillation or atrial flutter requiring hospitalization in a double-blind, placebo-controlled trial. The incidence of atrial fibrillation was greater in patients with a previous history of atrial fibrillation or atrial flutter

• It is not known whether patients with allergies to fish and/or shellfish are at an increased risk of an allergic reaction to VASCEPA. Patients with such allergies should discontinue VASCEPA if any reactions occur

INDICATIONS AND LIMITATIONS OF USE

• VASCEPA® (icosapent ethyl) is indicated as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥150 mg/dL) and established cardiovascular disease or diabetes mellitus and 2 or more additional risk factors for cardiovascular disease

• VASCEPA is indicated as an adjunct to diet to reduce TG levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia

The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.

• VASCEPA was associated with an increased risk (12% vs 10%) of bleeding in a double-blind, placebo-controlled trial. The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel or warfarin

• Common adverse reactions in the cardiovascular outcomes trial (incidence ≥3% and ≥1% more frequent than placebo): musculoskeletal pain (4% vs 3%), peripheral edema (7% vs 5%), constipation (5% vs 4%), gout (4% vs 3%) and atrial fibrillation (5% vs 4%)

• Common adverse reactions in the hypertriglyceridemia trials (incidence ≥1% more frequent than placebo): arthralgia (2% vs 1%) and oropharyngeal pain (1% vs 0.3%)

• Adverse Events, Product Complaints, or Special Situations may be reported by contacting AmarinConnect at 1-855-VASCEPA, emailing [email protected], or calling the FDA at 1-800-FDA-1088

• Patients receiving VASCEPA and concomitant anticoagulants and/or anti-platelet agents should be monitored for bleeding

Please see full Prescribing Information for more information on VASCEPA.

CV=cardiovascular; IPE=icosapent ethyl.
*Universal Pharmacy Card (UPC) may be applied for any eligible patient by entering all 4 codes into the notes section of an e-prescription.
Reference: 1. VASCEPA [package insert]. Bridgewater, NJ: Amarin Pharma, Inc.; 2021.

CO and VT prescribers only: Click here for statutory price disclosure information.

VASCEPA, Amarin, REDUCE-IT, and Vascepa/Amarin logos are registered trademarks of Amarin Pharmaceuticals Ireland Limited.

All other trademarks are the property of their respective companies.

© 2023 Amarin Pharmaceuticals Ireland Limited.  All rights reserved.  VAS-03038v14  02/23

This website, Vascepa.com, Vascepasavings.com, Truetoyourheart.com, and the corporation's website, amarincorp.com, are the only company-sanctioned websites pertaining to the Amarin group of companies or its product, Vascepa® (icosapent ethyl) capsules. The Amarin group of companies is not responsible for false or misleading materials contained on other non–Amarin-controlled websites or other social media sites.